Unknown

Dataset Information

0

Repurposing FDA-Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease.

ABSTRACT: Alzheimer's disease (AD) is one of the most common neurodegenerative causes of dementia, the pathology of which is still not much clear. It's challenging to discover the disease modifying agents for the prevention and treatment of AD over the years. Emerging evidence has been accumulated to reveal the crucial role of up-regulated glutaminyl cyclase (QC) in the initiation of AD. In the current study, the QC inhibitory potency of a library consisting of 1621 FDA-approved compounds was assessed. A total of 54 hits, 3.33 % of the pool, exhibited QC inhibitory activities. The Ki of the top 5 compounds with the highest QC inhibitory activities were measured. Among these selected hits, compounds affecting neuronal signaling pathways and other mechanisms were recognized. Moreover, several polyphenol derivatives with QC inhibitory activities were also identified. Frameworks and subsets contained in these hits were analyzed. Taken together, our results may contribute to the discovery and development of novel QC inhibitors as potential anti-AD agents.

SUBMITTER: Xu C 

PROVIDER: S-EPMC8409088 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Repurposing FDA-Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease.

Xu Chenshu C   Zou Haoman H   Yu Xi X   Xie Yazhou Y   Cai Jiaxin J   Shang Qi Q   Ouyang Na N   Wang Yinan Y   Xu Pan P   He Zhendan Z   Wu Haiqiang H  

ChemistryOpen 20201230 9

Alzheimer's disease (AD) is one of the most common neurodegenerative causes of dementia, the pathology of which is still not much clear. It's challenging to discover the disease modifying agents for the prevention and treatment of AD over the years. Emerging evidence has been accumulated to reveal the crucial role of up-regulated glutaminyl cyclase (QC) in the initiation of AD. In the current study, the QC inhibitory potency of a library consisting of 1621 FDA-approved compounds was assessed. A  ...[more]

Similar Datasets

Unknown Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells.
| S-EPMC10164021 | biostudies-literature
Transcriptomics Repurposing FDA-approved drugs for the treatment of malignant peripheral nerve sheath tumors
2023-10-21 | GSE159896 | GEO
Unknown Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
| S-EPMC8714248 | biostudies-literature
Unknown Potential COVID-19 papain-like protease PL<sup>pro</sup> inhibitors: repurposing FDA-approved drugs.
| S-EPMC7505060 | biostudies-literature
Unknown Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer's Disease.
| S-EPMC8571023 | biostudies-literature
Unknown Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer.
| S-EPMC8247203 | biostudies-literature
Unknown Discovery and Mechanistic Analysis of Structurally Diverse Inhibitors of Acetyltransferase Eis among FDA-Approved Drugs.
| S-EPMC9905294 | biostudies-literature
Unknown FDA Approved Drugs Repurposing of Toll-Like Receptor4 (TLR4) Candidate for Neuropathy.
| S-EPMC6934974 | biostudies-literature
Unknown Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
| S-EPMC5312272 | biostudies-literature
Unknown Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19).
| S-EPMC9057693 | biostudies-literature